Stuart Perry / Shutterstock.com
Market Herald logo

Subscribe

Be the first with the news that moves the market

Jatenergy released a high performing quarterly report and announcing a nine-month gross revenue to 31 March of $53.9 million.

Jatenergy is a company specialising in milk formula sales from Australia to China.

Gross revenue for the March 2019 quarter was $20.53m.

Jatenergy firmly stated the strong sales performance comes from a recent partnership with Chinese distributors HIT Crown. HIT Crown manages online medicine sales platform China Golden.

China Golden services over one million pharmaceutical companies, hospitals and consumers.

The company also announced two new sales agreements for its products. A five-year agreement with Guangzhou Niurui Trading Company has been signed.

This agreement will see Jatenergy formulas distributed into 150 Babemax maternal retail outlets.

Guangzhou will purchase 1.5 million tins of Neurio Lactoferrin milk powder. Jatenergy also signed a one-year agreement to sell through online store Bon Bon and its Wanwustore subsidiary.

The company expects to begin sales of a new milk formula for adults in May this year. Jatenergy also secured a trademark on Green Forest’s NSW sourced canola oil, to be released in May also.

Jatenergy’s ‘Golden Koala’ product range is currently selling well in the Chinese market. The company continues plans to establish a manufacturing plant in Australia.

Jatenergy rose 1.72 percent in the ASX today.

Please see the announcement attached

JAT by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.

" Breville Group (ASX:BRG) to acquire Italian specialty coffee company LELIT

Global coffee and appliance company Breville Group (ASX:BRG) have announced its finalised agreement to fully acquire…
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…

" COVID-19 costs bites into Bega Cheese’s (ASX:BGA) bottom line

COVID-19 related costs have bitten into Bega Cheese's (ASX:BGA) expected earnings for the 2022 financial year.